>
Juniper Pharmaceuticals Inc logo

JNP - Juniper Pharmaceuticals Inc Share Price

$11.5 0.0  0.0%

Last Trade - 13/08/18

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £39.3m
Position in Universe th / 6853
Bullish
Bearish
Unlock JNP Revenue
Momentum
Relative Strength (%)
1m -0.58%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 2018E 2019E CAGR / Avg
25.8 29.2 33.4 38.3 54.6 50.0 66.2 93.5 +14.1%
-35.4 -24.5 -42.9 +254.9 -92.2 +833.3
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2018, JuniperPharmaceuticals Inc revenues increased 22% to $30.8M. Netloss applicable to common stockholders decreased 46% to$742K. Revenues reflect Services segment increase of 41% to$11.2M, Product segment increase of 14% to $19.7M, UnitedStates segment increase of 86% to $7.5M, Switzerlandsegment increase of 13% to $19.8M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

JNP Revenue Unlock JNP Revenue

Net Income

JNP Net Income Unlock JNP Revenue

Normalised EPS

JNP Normalised EPS Unlock JNP Revenue

PE Ratio Range

JNP PE Ratio Range Unlock JNP Revenue

Dividend Yield Range

JNP Dividend Yield Range Unlock JNP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
JNP EPS Forecasts Unlock JNP Revenue
Profile Summary

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.

Directors
Last Annual December 31st, 2017
Last Interim June 30th, 2018
Incorporated December 30, 1986
Public Since July 28, 1988
No. of Shareholders: 4,700
No. of Employees: 155
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange NASDAQ Global Select Market
Shares in Issue 11,319,757
Free Float (0.0%)
Eligible for
ISAs
SIPPs
JNP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for JNP
Upcoming Events for JNP
Frequently Asked Questions for Juniper Pharmaceuticals Inc
What is the Juniper Pharmaceuticals Inc share price?

As of 13/08/18, shares in Juniper Pharmaceuticals Inc are trading at $11.5, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Juniper Pharmaceuticals Inc share price performed this year?

Shares in Juniper Pharmaceuticals Inc are currently trading at $11.5 and the price has moved by 0.158k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Juniper Pharmaceuticals Inc price has moved by 77.09% over the past year.

What are the analyst and broker recommendations for Juniper Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Juniper Pharmaceuticals Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Juniper Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Juniper Pharmaceuticals Inc next release its financial results?

Juniper Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2019-06-30
What is the Juniper Pharmaceuticals Inc dividend yield?

Juniper Pharmaceuticals Inc does not currently pay a dividend.

Does Juniper Pharmaceuticals Inc pay a dividend?

Juniper Pharmaceuticals Inc does not currently pay a dividend.

When does Juniper Pharmaceuticals Inc next pay dividends?

Juniper Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Juniper Pharmaceuticals Inc shares?

To buy shares in Juniper Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Juniper Pharmaceuticals Inc?

Shares in Juniper Pharmaceuticals Inc are currently trading at $11.5, giving the company a market capitalisation of £n/a.

Where are Juniper Pharmaceuticals Inc shares listed? Where are Juniper Pharmaceuticals Inc shares listed?

Here are the trading details for Juniper Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: JNP
What kind of share is Juniper Pharmaceuticals Inc?

We were not able to load our ranking data for Juniper Pharmaceuticals Inc

Is there a Juniper Pharmaceuticals Inc share price forecast 2021?

We were not able to load any forecast data for Juniper Pharmaceuticals Inc.

How can I tell whether the Juniper Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Juniper Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 13.14%. At the current price of $11.5, shares in Juniper Pharmaceuticals Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Juniper Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Juniper Pharmaceuticals Inc.

Who are the key directors of Juniper Pharmaceuticals Inc?

We were unable to find the directors for Juniper Pharmaceuticals Inc.

Who are the major shareholders of Juniper Pharmaceuticals Inc?

Here are the top five shareholders of Juniper Pharmaceuticals Inc based on the size of their shareholding:

Similar to JNP
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.